1.43% -0.335

Harrow Inc (HROW)

개요 뉴스 가격 이력 옵션 체인 Financials HROW 왜 하락? 토론 예측 주식 분할

Relative Volume:

Harrow Inc Stock (HROW) Company Profile

Healthcare (1173)

615.733.4731

102 WOODMONT BLVD, NASHVILLE, CA

최신 SEC 제출 서류

HROW's Discussions on Twitter

HROW을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
HROW Harrow Inc	25.46	904.29M	154.15M	-33.58M	-20.74M	-0.96
ZTS Zoetis Inc	157.20	68.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.35	47.71B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.60	46.12B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.41	18.55B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	295.78	13.40B	2.76B	1.11B	898.10M	22.77

Harrow Inc Stock (HROW) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-02-06	개시	H.C. Wainwright	Buy
2024-12-04	재확인	B. Riley Securities	Buy
2024-04-11	개시	Craig Hallum	Buy
2022-09-08	재개	B. Riley Securities	Buy
2021-10-14	재개	B. Riley Securities	Buy
2021-09-24	개시	Aegis Capital	Buy
2021-07-02	개시	Ladenburg Thalmann	Buy

Harrow Inc 주식(HROW)의 최신 뉴스

Harrow Inc (HROW) 재무 분석

Harrow Inc 주식 (HROW) 내부자 거래

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
SAHAREK JOHN P.	CEO & President, ImprimisRx	Apr 03 '25	Option Exercise	0.00	277,200	0	576,863
BAUM MARK L	Chief Executive Officer	Apr 03 '25	Option Exercise	0.00	762,300	0	2,899,825
Opaleye Management Inc.	10% Owner	Mar 18 '25	Sale	30.01	5,000	150,055	140,000
Opaleye Management Inc.	10% Owner	Mar 18 '25	Sale	29.64	5,000	148,200	145,000
Opaleye Management Inc.	10% Owner	Feb 28 '25	Sale	28.05	5,000	140,250	150,000
Opaleye Management Inc.	10% Owner	Jan 22 '25	Sale	35.59	20,000	711,814	155,000
SAHAREK JOHN P.	CEO of ImprimisRx	Sep 11 '24	Option Exercise	7.37	90,000	663,300	344,803

Harrow Inc (HROW)

Harrow Inc Stock (HROW) Company Profile

HROW을(를) 다른 주식과 비교

Harrow Inc Stock (HROW) Upgrades & Downgrades

Harrow Inc 주식(HROW)의 최신 뉴스

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 | HROW Stock News - GuruFocus

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - Business Wire

Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - MSN

JPMorgan Chase & Co. Lowers Stock Position in Harrow, Inc. (NASDAQ:HROW) - Defense World

Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic L - GuruFocus

Harrow Authorizes Nordic Group Unit to sell Generic Version of Maxitrol eye Treatment - marketscreener.com

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) – Company Announc - Financial Times

LPL Financial LLC Has $699,000 Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives Propel Success - GuruFocus

Harrow Inc (NASDAQ: HROW) Jumps 2.74%: The Most Likely Path Going Forward - Stocksregister

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire

Where Harrow Stands With AnalystsHarrow (NASDAQ:HROW) - Benzinga

B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating - MarketScreener

H.C. Wainwright maintains $57 target on Harrow Health stock - Investing.com

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives By GuruFocus - Investing.com Canada

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Harrow Health Reports Strong 2024 Financial Performance - TipRanks

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha

Harrow Health (HROW) Gets a Buy from Craig-Hallum - The Globe and Mail

Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Harrow: Q4 Earnings Snapshot - The Advocate

Harrow Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Joplin Globe

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 - Business Wire

Harrow Inc. sees $150k stock sale by Opaleye Management - Investing.com

Harrow Inc (HROW) Shares Gap Down to $27.235 on Mar 26 - GuruFocus

Harrow sees shares increase following drug approval - Nashville Post

Craig-Hallum Reaffirms Their Buy Rating on Harrow Health (HROW) - The Globe and Mail

CMS approves separate reimbursement for Harrow’s TRIESENCE - Investing.com

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire

Harrow Inc (HROW) Shares Up 1.14% on Mar 22 - GuruFocus

Opaleye management sells $148,200 in Harrow, Inc. stock - Investing.com India

What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus

Opaleye Management Inc. Adjusts Stake in Harrow Inc. - GuruFocus

Bank of New York Mellon Corp Has $2.90 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World

Harrow Inc (HROW) Shares Up 2.97% on Mar 21 - GuruFocus

Opaleye management sells $148,200 in Harrow, Inc. stock By Investing.com - Investing.com South Africa

Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha

H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target By Investing.com - Investing.com Australia

H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target - Investing.com India

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial - GlobeNewswire Inc.

Harrow stock surges on preliminary Q4 numbers - Nashville Post

Harrow Inc (HROW) 재무 분석

매출

순이익

현금흐름

주당 순 이익

Harrow Inc 주식 (HROW) 내부자 거래

HROW과 유사한 종목